clinical trial · NCT07519395
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
GlaxoSmithKline·phase2·not yet recruiting·n = 420
Irritable Bowel SyndromePlaceboCamlipixant
brief summary
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.
started
Apr 6, 2026
primary completion
Mar 5, 2027
completion
Jul 9, 2027
last updated
Apr 9, 2026
official title
BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol